A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Sylvia Adams; Megan Othus; Sandip Pravin Patel; Kathy D. Miller; Rashmi Chugh; Scott M. Schuetze; Mary D. Chamberlin; Barbara J. Haley; Anna Maria V. Storniolo; Mridula P. Reddy; Scott A. Anderson; Collin T. Zimmerman; Anne P. O’Dea; Hamid R. Mirshahidi; Jordi Rodon Ahnert; Frank J. Brescia; Olwen Hahn; Jane M. Raymond; David D. Biggs; Roisin M. Connolly; Elad Sharon; Larissa A. Korde; Robert J. Gray; Edward Mayerson; Melissa Plets; Charles D. Blanke; Young Kwang Chae; Razelle Kurzrock

doi:10.1158/1078-0432.CCR-21-2182

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

Sylvia Adams, Megan Othus, Sandip Pravin Patel, Kathy D. Miller, Rashmi Chugh, Scott M. Schuetze, Mary D. Chamberlin, Barbara J. Haley, Anna Maria V. Storniolo, Mridula P. Reddy, Scott A. Anderson, Collin T. Zimmerman, Anne P. O’Dea, Hamid R. Mirshahidi, Jordi Rodon Ahnert, Frank J. Brescia, Olwen Hahn, Jane M. Raymond, David D. Biggs, Roisin M. ConnollyElad Sharon, Larissa A. Korde, Robert J. Gray, Edward Mayerson, Melissa Plets, Charles D. Blanke, Young Kwang Chae, Razelle Kurzrock

Hematology/Oncology Division

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	271-278
Number of pages	8
Journal	Clinical Cancer Research
Volume	28
Issue number	2
DOIs	https://doi.org/10.1158/1078-0432.CCR-21-2182
State	Published - Jan 15 2022

ASJC Scopus Subject Areas

General Medicine

Access to Document

10.1158/1078-0432.CCR-21-2182

OpenUrl availability

Full text

Cite this

Adams, S., Othus, M., Patel, S. P., Miller, K. D., Chugh, R., Schuetze, S. M., Chamberlin, M. D., Haley, B. J., Storniolo, A. M. V., Reddy, M. P., Anderson, S. A., Zimmerman, C. T., O’Dea, A. P., Mirshahidi, H. R., Ahnert, J. R., Brescia, F. J., Hahn, O., Raymond, J. M., Biggs, D. D., ... Kurzrock, R. (2022). A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609). Clinical Cancer Research, 28(2), 271-278. https://doi.org/10.1158/1078-0432.CCR-21-2182

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609). / Adams, Sylvia; Othus, Megan; Patel, Sandip Pravin et al.
In: Clinical Cancer Research, Vol. 28, No. 2, 15.01.2022, p. 271-278.

Research output: Contribution to journal › Article › peer-review

Adams, S, Othus, M, Patel, SP, Miller, KD, Chugh, R, Schuetze, SM, Chamberlin, MD, Haley, BJ, Storniolo, AMV, Reddy, MP, Anderson, SA, Zimmerman, CT, O’Dea, AP, Mirshahidi, HR, Ahnert, JR, Brescia, FJ, Hahn, O, Raymond, JM, Biggs, DD, Connolly, RM, Sharon, E, Korde, LA, Gray, RJ, Mayerson, E, Plets, M, Blanke, CD, Chae, YK & Kurzrock, R 2022, 'A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)', Clinical Cancer Research, vol. 28, no. 2, pp. 271-278. https://doi.org/10.1158/1078-0432.CCR-21-2182

@article{684eb127385440738ccf555f32a034e7,

title = "A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)",

author = "Sylvia Adams and Megan Othus and Patel, {Sandip Pravin} and Miller, {Kathy D.} and Rashmi Chugh and Schuetze, {Scott M.} and Chamberlin, {Mary D.} and Haley, {Barbara J.} and Storniolo, {Anna Maria V.} and Reddy, {Mridula P.} and Anderson, {Scott A.} and Zimmerman, {Collin T.} and O{\textquoteright}Dea, {Anne P.} and Mirshahidi, {Hamid R.} and Ahnert, {Jordi Rodon} and Brescia, {Frank J.} and Olwen Hahn and Raymond, {Jane M.} and Biggs, {David D.} and Connolly, {Roisin M.} and Elad Sharon and Korde, {Larissa A.} and Gray, {Robert J.} and Edward Mayerson and Melissa Plets and Blanke, {Charles D.} and Chae, {Young Kwang} and Razelle Kurzrock",

note = "Publisher Copyright: {\textcopyright} 2021 American Association for Cancer Research.",

year = "2022",

month = jan,

day = "15",

doi = "10.1158/1078-0432.CCR-21-2182",

language = "English",

volume = "28",

pages = "271--278",

journal = "Clinical Cancer Research",

issn = "1078-0432",

number = "2",

}

TY - JOUR

T1 - A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer

T2 - Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

AU - Adams, Sylvia

AU - Othus, Megan

AU - Patel, Sandip Pravin

AU - Miller, Kathy D.

AU - Chugh, Rashmi

AU - Schuetze, Scott M.

AU - Chamberlin, Mary D.

AU - Haley, Barbara J.

AU - Storniolo, Anna Maria V.

AU - Reddy, Mridula P.

AU - Anderson, Scott A.

AU - Zimmerman, Collin T.

AU - O’Dea, Anne P.

AU - Mirshahidi, Hamid R.

AU - Ahnert, Jordi Rodon

AU - Brescia, Frank J.

AU - Hahn, Olwen

AU - Raymond, Jane M.

AU - Biggs, David D.

AU - Connolly, Roisin M.

AU - Sharon, Elad

AU - Korde, Larissa A.

AU - Gray, Robert J.

AU - Mayerson, Edward

AU - Plets, Melissa

AU - Blanke, Charles D.

AU - Chae, Young Kwang

AU - Kurzrock, Razelle

PY - 2022/1/15

Y1 - 2022/1/15

UR - http://www.scopus.com/inward/record.url?scp=85123369221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85123369221&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-21-2182

DO - 10.1158/1078-0432.CCR-21-2182

M3 - Article

C2 - 34716198

AN - SCOPUS:85123369221

SN - 1078-0432

VL - 28

SP - 271

EP - 278

JO - Clinical Cancer Research

JF - Clinical Cancer Research

IS - 2

ER -

A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti–CTLA-4 and Anti–PD-1 Blockade in Rare Tumors (DART, SWOG S1609)

ASJC Scopus Subject Areas

Access to Document

OpenUrl availability

Other files and links

Cite this